Below you'll find case studies, webinars, blogs, and press releases where we share valuable insights about decentralized clinical trials.
ObvioHealth, a pioneering virtual research organization, announces the launch of a proprietary application programming interface (API) tailored specifically for digital therapeutic (DTx) clinical trials.
Patient engagement in clinical trials can make or break a study. Engaged patients are more likely to participate and complete studies, which can strengthen data collection and, ultimately, provide more robust therapeutic evidence of safety and efficacy.
Clinical trials lay the foundation for breakthrough drugs, digital therapeutics, and medical devices—and, at the center of these studies are the patients.
ObvioHealth and Sterling IRB today announce a partnership to help speed access and adoption of decentralized clinical trials. The partnership makes Sterling IRB the preferred Institutional Review Board for ObvioHealth.
In three short years, decentralized clinical trials (DCTs) have turned skeptics into believers. Trial sponsors who were once hesitant are now embracing the DCT model—and for good reason. Today’s DCTs are addressing longstanding industry challenges, expanding access to patients and clinicians, increasing diversity, accelerating cohort recruitment, and improving retention.
When it comes to decentralized clinical trials (DCTs), the pharmaceutical industry finds itself at a crossroads.
Medical device trials are inherently challenging, particularly in women's health. But, within the context of a pandemic, the hurdles may seem insurmountable.
How Cutting-Edge Digital Instruments Can Optimize Data Collection and Improve Outcome Accuracy